Disposition of polyoxyethylated excipients in humans: Implications for drug safety and formulation approaches

Clinical Pharmacology and Therapeutics

Volumn 74, Issue 5, 2003, Pages 509-510

  Ten Tije, Albert J ^a   Loos, Walter J ^a   Verweij, Jaap ^a   Baker, Sharyn D ^b   Dinh, Kimberly ^b   Figgs, William D ^c   Sparreboom, Alex ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREMOPHOR; DOCETAXEL; PACLITAXEL; POLYSORBATE 80;

AREA UNDER THE CURVE; CANCER; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; HUMAN; LETTER; MAJOR CLINICAL STUDY; NEUROPATHY; PRIORITY JOURNAL;

AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; EXCIPIENTS; HALF-LIFE; HUMANS; POLYETHYLENE GLYCOLS; POLYSORBATES;

EID: 0242319813     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2003.08.004     Document Type: Letter

References (10)

1. Baldrick P. Pharmaceutical excipient development: the need for preclinical guidance. Regul Toxicol Pharmacol 2000;32:210-8.
2. Wandel C, Kim RB, Stein CM. "Inactive" excipients such as Cremophor can affect in vivo drug disposition. Clin Pharmacol Ther 2003;73:394-6.
3. Tayrouz Y, Ding R, Burhenne J, Riedel K-D, Weiss J, Hoppe-Tichy T, et al. Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40. Clin Pharmacol Ther 2003;73:397-405.
4. Loos WJ, Baker SD, Verweij J, Boonstra JG, Sparreboom A. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin Pharmacol Ther 2003;74: 364-71.
5. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003;42:665-85.
6. Sparreboom A, Zhao M, Brahmer JR, Verweij J, Baker SD. Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002;773:183-90.
7. Sparreboom A, Loos WJ, Verweij J, de Vos AI, van der Burg ME, Stoter G, et al. Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay. Anal Biochem 1998;255:171-5.
8. Sparreboom A, Verweij J, van der Burg ME, Loos WJ, Brouwer E, Vigano L, et al. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin Cancer Res 1998;4:1937-42.
9. Szebeni J. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radio-contrast agents. Crit Rev Ther Drug Carrier Syst 2001;18:567-606.
10. Windebank AJ, Blexrud MD, de Groen PG. Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol Exp Ther 1994;268:1051-6.